New hope for kids with tough neuroblastoma: drug combo trial launches
NCT ID NCT07437963
First seen Mar 12, 2026 · Last updated May 03, 2026 · Updated 7 times
Summary
This study tests whether adding iberdomide to standard chemoimmunotherapy is safe and works better for children and young adults (ages 1–30) with neuroblastoma that has come back or not responded to prior treatment. About 76 participants will receive either the standard treatment or the standard plus iberdomide. The goal is to see if the new combination can shrink tumors or stop the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.